Stemline Therapeutics (STML) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Affirms Stemline Therapeutics (STML) at 'Buy'; Focus Now on June ASCO Presentation
May 9, 2016 11:43 AM EDTRoth Capital affirms Stemline Therapeutics (Nasdaq: STML) with a Buy rating and $32 price target after the company reported Q1 results on Monday. Stemline posted Q1 EPS of ($0.51), which was $0.08 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $205.65 million, versus $121.43 million reported last year.
Analyst Joseph Pantginis commented, Following a mostly quiet time in 2015 regarding news flow, which we... More
